LNCB74 — Initial data
H2 2026
LNCB74 Phase 1 dose escalation trial update planned in second half of 2026Source filing
NXTC biotech catalysts & pipeline
NEXTCURE INC · Data as of 2026-10-25
Upcoming catalysts
AVR-001 — Clinical data readout
2027
A Phase 2b psoriasis study in China conducted by Hansoh is also expected to read out in 2027.Source filing
AVR-001 — Clinical data readout
H1 2028
A US IND for AVR-001 is open, and initiation of the Phase 2b study by Avere is anticipated in early 2027, with an expected readout in the first half of 2028.Source filing